Dendreon Names Ernest Bognar General Manager of Hanover, NJ Manufacturing Facility

09-Mar-2006

Dendreon Corporation announced that it named Ernest A. Bognar general manager of the Company's new manufacturing facility in Hanover, New Jersey. Dendreon is currently developing this facility to meet the anticipated clinical and commercial manufacturing needs for PROVENGE® (sipuleucel-T) and its other active immunotherapy product candidates in development. PROVENGE is the Company's lead investigational active cellular immunotherapy for the potential treatment of advanced prostate cancer.

Bognar recently served as vice president of manufacturing at Apptec Laboratory Services where he was brought on board to manage and grow a mammalian cell-based contract manufacturing business unit. Prior to that, he was senior director commercial manufacturing for ImClone Systems Inc., where he managed a biopharmaceutical start-up operation that produced the company's monoclonal antibody, ERBITUX® (cetuximab) Injection for the treatment of colorectal cancer. Previously, he served as director of operations at Baxter Healthcare's Hyland-Immuno Division where he managed a commercial biopharmaceutical operation producing a licensed recombinant protein for the treatment of hemophilia. Bognar also held key manufacturing positions at Cellex Biocences & Verax, Charles River Biotech & KC Biological and Ayerst Research Laboratories.

He received his Bachelor's of Science degree in in vitro cell biology from the State University of New York of Arts and Sciences at Plattsburgh and his Cell Biology Certificate from W. Alton Jones Cell Science Center in Lake Placid, NY.

Other news from the department manufacturing

Most read news

More news from our other portals

Fighting cancer: latest developments and advances